Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Upadacitinib Safety Similar to Other Jakinibs for RA

Lisa Rapaport  |  November 16, 2020

(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…

Filed under:Drug Updates Tagged with:JAK inhibitorsjakinibRheumatoid Arthritis (RA)upadacitinib

RA Patients with ILD & Liver Disease Present Treatment Challenges

Vanessa Caceres  |  November 12, 2020

ACR CONVERGENCE 2020—Patients with concurrent rheumatological arthritis (RA) and liver disease or interstitial lung disease or treatment-refractory rheumatoid arthritis pose treatment challenges, according to the panelists of the ACR Convergence 2020’s How I Treat Difficult RA: Panel Session. Each panelist discussed a difficult case and raised questions on how to best treat it. Joan M….

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Advantages of Embedding a Specialty Pharmacist in a Rheumatology Clinic

Polly J. Ferguson, MD, Jessica Lynton, PharmD, BCPS, & Beth H. Resman-Targoff, PharmD, FCCP, on behalf of the ARP Membership & Nominations Committee  |  November 12, 2020

The number of medications with rheumatologic indications has increased in parallel with expanding complexities of medication approval and delivery. Simply starting a patient on a biologic medication or new disease-modifying anti-rheumatic drug (DMARD) can be time consuming and frustrating for physicians, nurses and their support staff. In addition to educating the patient and obtaining prior…

Filed under:Drug UpdatesFrom the CollegePractice Support Tagged with:adherenceAssociation of Rheumatology Professionals (ARP)pharmacistprior authorization

Rheumatologist in India Finds the Patient Global Assessment Challenging

Anand N. Malaviya, MD, FRCP, ACR Master  |  November 12, 2020

It was a delight to read the comments in the May 2019 issue of The Rheumatologist on a paper by Hirsch and colleagues, discussing how health literacy affects the patient global assessment.1,2 Patient-driven outcome measures (PROs), patient global assessment on a visual analog scale (VAS) or a numeric rating scale (NRS), a segmented numeric version…

Filed under:Conditions Tagged with:health literacypatient global assessment

The 2020 ACR Awards of Distinction & Masters Class

Linda Childers  |  November 12, 2020

Presidential Gold Medal The highest award the ACR can bestow, the Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. This year’s award went to James O’Dell, MD, the Stokes-Shackleford Professor of Internal Medicine, vice chair of internal medicine and chief of the Division of Rheumatology at the…

Filed under:Awards Tagged with:ACR Convergence 2020Ciarán M. DuffyDr. Abby AbelsonDr. Ami Aalok ShahDr. Andras PerlDr. Angela TincaniDr. Bernardo A. Pons-EstelDr. Brian F. MandellDr. Carlos J. LozadaDr. Daniel SolomonDr. Edward K.L. ChanDr. Emily IsaacsDr. James O’DellDr. James R. SeiboldDr. James WitterDr. Joanne M. JordanDr. Kara PetersenDr. Kathleen M. O’NeilDr. Leonard H. SigalDr. M. Virginia PascualDr. Martin Jan BergmanDr. Michael B. BrennerDr. Nancy E. LaneDr. Norman T. IlowiteDr. Pamela WeissDr. Pierre MiossecDr. Robert W. WarrenDr. Sheldon SolomonDr. Stuart Kassan

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  November 9, 2020

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2020ACR Convergence 2020 - SLEACR Convergence 2020 – RA

Gout: The State of the Science

Keri Losavio  |  October 26, 2020

In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

Filed under:ACR ConvergenceGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2020 – Gout

FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2020

The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalGolimumabPediatricpolyarticular juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis (JIA)Psoriatic ArthritisU.S. Food and Drug Administration (FDA)

Reflections on Starting a Rheumatology Fellowship During the Pandemic

Nicole K. Zagelbaum Ward, DO, MPH, with Richard S. Panush, MD, MACP, MACR  |  October 19, 2020

Some have opined, cynically, that transformative changes will not come to medical education and training, and to healthcare, until pigs fly. Well, in 2009–10, “swine flu,” and now we are in the midst of an unprecedented and disruptive pandemic, affecting virtually all aspects of our lives, including fellowships.1 As someone who started a rheumatology fellowship…

Filed under:Education & TrainingProfessional Topics Tagged with:Fellows-in-Training

Case Report: A 40-Year-Old Man with Vasculitic Neuropathy

Case Report: A 40-Year-Old Man with Vasculitic Neuropathy

Martin Garber, DO, & David Fivenson, MD  |  October 19, 2020

Ironically, chronic exposure to minocycline has also been associated with a variety of autoimmune syndromes, including drug-induced lupus, auto­immune hepatitis, serum sickness and vasculitis.1 Minocycline is associated with an 8.5-fold increased risk of drug-induced lupus.2 Minocycline and nitrofurantoin are implicated in 90% of cases of drug-induced autoimmune hepatitis.3 Minocycline-induced vasculitis is much less common and,…

Filed under:ConditionsVasculitis Tagged with:minocyclinepolyarteritis nodosavasculitic neuropathy

  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences